SAB Biotherapeutics (SABS) Enters $20M Equity Sales Agreement

SAB Biotherapeutics (NASDAQ: SABS) entered into a Controlled Equity Offering℠ Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor” or the “sales agent”), relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $20,000,000 from time to time through Cantor, acting as our sales agent, pursuant to this prospectus supplement.

You May Also Be Interested In

• Decent Holding prices $1.23M follow-on share offering on Nasdaq
• Marfrig unit cancels tender offer for $467M in senior notes
• Verra Mobility names Jon Newhard as president and CEO